Compare Cassava Sciences Inc (FLNA) vs Wolfspeed Inc (WOLF) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

Wolfspeed (WOLF) trades at $31.23, down 0.45% on the day, with a bullish technical signal driven by moving averages. The company reported a significant net loss of -$1.61B in 2025, with negative gross and net profit margins, though 2026 projections show potential for a small profit. Recent news highlights expansion of its 200mm silicon carbide portfolio, positioning it in the growing AI infrastructure sector.

The outlook is mixed; analyst consensus is a Buy with a $54.32 price target, suggesting substantial upside, but high execution risk remains due to persistent losses and ongoing legal investigations. Revenue growth and achieving profitability are critical for stock performance, with the transition to 800-volt AI data centers being a potential catalyst.